ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test

Rapid Immunoassay for Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Influenza Type B Antigens

For In Vitro Diagnostic Use For Rx Use Only For Use Under an Emergency Use Authorization Only

INTENDED USE

ViraDx[™] SARS-CoV-2/Flu A+B Rapid Antigen Test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid protein antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal or nasopharyngeal swab specimens collected from individuals, who are suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider, within the first five (5) days of onset of symptoms, when tested at least twice over three days with at least 48 hours between tests. Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2.

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation.

The ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test does not differentiate between SARS-CoV or SARS-CoV-2 viruses.

Results are for the simultaneous in vitro detection and differentiations of nucleocapsid protein antigens of SARS-CoV-2, influenza A and influenza B, and is not intended to detect influenza C antigens. These viral antigens are generally detectable in anterior nasal or nasopharyngeal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of the disease.

All negative SARS-CoV-2 results are presumptive and should be confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks. Negative results should be considered in the context of a patient's recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.

All negative influenza A and B test results are presumptive. It is recommended these results be confirmed by an FDA-cleared influenza A and B molecular assay. Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other management decisions.

Performance characteristics for influenza A and B were established during the 2007-2009 and the 2014-2016 influenza seasons when influenza A/H1N1, A/H1N1 pandemic, A/H3N2, influenza B/Victoria lineage and B/Yamagata lineage were the predominant influenza viruses in circulation according to the Flu Activity & Surveillance reports from the CDC. When other influenza viruses are emerging, performance characteristics may vary.

If infection with a novel influenza virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. A viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.

ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test is intended for use by medical professionals and laboratory personnel trained to perform the test. ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test is only for in vitro diagnostic use under the Food and Drug Administration's Emergency Use Authorization. This product has not been FDA cleared or approved.

SUMMARY AND EXPLANATION

Influenza is a highly contagious acute viral infection of the respiratory tract. It is a communicable disease easily transmitted from person to person through aerosol droplets excreted when sneezing and coughing. Common symptoms include high fever, chills, headache, cough, sore throat and malaise. The type A influenza virus is more prevalent and is the primary pathogen associated with serious epidemics. The type B virus causes a disease that is generally not as severe as that caused by the type A virus.

An accurate diagnosis of influenza based on clinical symptoms is difficult because the initial symptoms of influenza are similar to those of numerous other illnesses. Therefore, it can be confirmed only by laboratory diagnostic testing.1 Early differential diagnosis of influenza

type A or type B can allow for proper treatment with appropriate antiviral therapy while reducing the incidence of inappropriate treatment with antibiotics. Early diagnosis and treatment are of particular value in a clinical setting where an accurate diagnosis can assist the healthcare professional with the management of influenza patients who are at risk for complications.2

In December 2019, a cluster of atypical pneumonia patients epidemiologically linked to a wet market in Wuhan (Hubei province, China) was detected. Initially, the novel coronavirus was named 2019-nCoV. Later it was named the SARS-CoV-2 virus, as it is very similar to the one that caused the outbreak of severe acute respiratory disease (SARS) in 2003. At the end of January 2020, the World Health Organization (WHO) declared the new infectious disease COVID-19 a global emergency. On March 11, 2020, the WHO recognized the new infectious disease as a pandemic. COVID-19 has demonstrated the capability of spreading rapidly, leading to significant impacts on the healthcare system and causing societal disruption. The ongoing COVID-19 pandemic has infected millions of people worldwide. To respond effectively to the COVID-19 outbreak, rapid detection of cases, stringent performance assessment and increase in the current diagnostic capacity are still urgently needed. The symptoms of COVID-19 are similar to those of other viral respiratory disease and include fever or chills, cough, shortness of breath or difficulty of breathing, fatigue, muscle or body aches, headache, the new loss of taste or smell, sore throat, congested or runny nose, nausea or vomiting or diarrhea, etc. As the early symptoms of COVID-19 are similar to those of seasonal influenza A or B, a rapid detection test to specifically diagnose symptomatic patients is urgently needed.

The performance of this test was established based on the evaluation of a limited number of clinical specimens. Clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.

PRINCIPLE OF PROCEDURE

ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test is a modification of the FDA 510(k) cleared device, Status Flu A&B, initially cleared on 11/10/2010 (K083746). Modifications of the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test device consists of: 1.) the addition of a test line of monoclonal antibody and a pad containing monoclonal antibody-dye conjugate for the detection of SARS-CoV-2 antigen from anterior nasal or nasopharyngeal swab patient specimen and 2.) modification to the plastic cassette housing and test steps such that samples are applied to the test cassette via extraction tube rather than directly applying swabs to the extraction well of the cassette. ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test is intended to aid in the rapid differential diagnosis of influenza A, B and SARS-CoV-2 viral infection. ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test is a lateral flow immuno-chromatographic assay which utilizes the chemical extraction of viral antigens followed by solid-phase immunoassay technology. ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test is designed to detect antigens from SARS-CoV-2, influenza A and /or influenza B in anterior nasal or nasopharyngeal swab specimens from individuals with signs and symptoms of respiratory infection, suspected of COVID-19 or flu by their healthcare provider, within the first five days of onset of symptoms. It is intended to aid in the rapid differential diagnosis of SARS-CoV-2/Flu A+B Rapid Antigen Test is validated for use with direct specimens without transport media.

In the test procedure, an anterior or nasopharyngeal swab specimen is collected and placed into an Extraction Tube filled with Extraction Reagent for one minute. During this time the antigen is extracted from disrupted virus particles. The Extraction Tube is then inverted and the solution is applied to the test device. The solution of extracted specimen flows onto the test strip and migrates through the pads and membrane of the test strip. The pads contain detector antibodies conjugated to gold dye and the membrane contains immobilized capture antibodies. If SARS-CoV-2,

influenza A and/or influenza B antigens are present in the specimen, they will react with anti-SARS-CoV-2 antibody coupled to gold dye particles and/or anti-influenza antibody coupled to gold dye particles, migrate through the membrane as antigen-antibody-dye complexes, bind to the immobilized capture antibody line(s) on the membrane, and generate a colored line in the specific test line position. The rest of the sample and unbound/bound dye complexes continue to migrate to the Control line position (C), where immobilized antibodies to the anti-SARS-CoV-2 and anti-influenza antibodies capture the dye complexes and form the Control line. Formation of the Control line serves as an internal control to demonstrate that test reagents are functional, antibody-dye conjugates in the dye pad have been hydrated and released and that sufficient sample has been applied to allow for migration through the Test and Control lines. If the Control line does not appear within the designated incubation time, the result is invalid and the test should be repeated using a new test device and specimen. ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test has three Test lines, one for SARS-CoV-2, one for influenza A and one for influenza B. The three Test lines allow for the separate and differential identification of SARS-CoV-2, influenza A and/or B from a single specimen. If any Test line appears in the test result window, together with the Control line, the test result is positive for SARS-CoV-2 and/or influenza. The test detects, but does not differentiate, between the SARS-CoV and SARS-CoV-2 viruses.

REAGENTS

Each ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test kit contains enough reagents and materials for 25 tests. The following components are included in a kit.

MATERIALS PROVIDED

25 ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test devices. The test strip in each device contains mouse monoclonal antibodies to nucleocapsid protein of influenza A, influenza B and SARS-CoV-2. Each test strip is single-use and device is individually pouched.	
25 Extraction Reagent Capsules. For use with swab specimens; 300 μL of Phosphate buffer with detergents and preservative.	
25 Extraction Reagent Tubes. For preparing specimen.	
25 Sterile Swabs. For swab specimen collection.	
1 Positive Control Swab. Influenza A, B and SARS-CoV-2 antigen (non-infective recombinant nucleocapsid).	
1 Negative Control Swab. Inactivated Group B Streptococcus antigen (non-infective).	
1 Package Insert.	
1 Quick Reference Instructions.	

WARNINGS AND PRECAUTIONS

- 1. For in vitro diagnostic use.
- 2. For prescription use only.
- 3. For use under FDA Emergency Use Authorization only
- 4. This product has not been FDA cleared or approved, but has been authorized by FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories; laboratories certified under CLIA that meet the requirements to perform moderate, high or waived complexity tests. This product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation. This product has been authorized only for the detection of proteins from SARS-CoV- 2, influenza A, and influenza B, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.
- Serial testing should be performed in individuals with negative results at least twice over three days (with 48 hours between tests) for symptomatic individuals. You may need to purchase additional tests to perform this serial (repeat) testing.
- 6. Consistent with serial testing recommendations for SARS-CoV-2, for multi-analyte tests, symptomatic individuals who test positive for influenza A or B on the initial test but test negative for SARS-CoV-2 should be tested again in 48 hours to evaluate for co-infection with SARS-CoV-2 infection.
- 7. Do not use after the expiration date printed on the outside of the box.
- 8. Read all instructions carefully before performing the test. Failure to follow the instructions may result in inaccurate test results.
- 9. Ensure that there is sufficient lighting for testing and interpretation.
- ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test is only intended for use with direct anterior nasal or nasopharyngeal swab specimens and is not validated or authorized for use with viral transport media. Use only the swabs provided for collecting specimens. Other swabs may not work properly.
- 11. Test components are single-use. Do not reuse used test devices, swabs, extraction tubes or control swabs.
- 12. Inadequate or inappropriate sample collection, storage and transport may yield false test results.

MATERIALS REQUIRED, BUT NOT PROVIDED

Timer

- To obtain accurate results, the Package Insert instructions must be followed. Failure to follow the instructions may result in inaccurate test results.
- 14. The ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test device should remain in its original sealed pouch until ready for use. Once opened, the test should be used immediately. Do not use the test if the seal is broken or the pouch is damaged.
- 15. Do not read test results before 15 minutes or after 20 minutes. Results read before 15 minutes or after 20 minutes may lead to a false positive, false negative, or invalid result.
- 16. Dispose of containers and unused contents in accordance with federal, state and local regulatory requirements.
- 17. Do not smoke, eat or drink in areas in which specimens or kit reagents are handled. Extraction Reagent is slightly caustic. Avoid contact with eyes, sensitive mucous membranes, cuts, abrasions, etc. If the reagent comes in contact with skin or eyes, flush with a large volume of water. Do not ingest any kit components. The reagent solution contains harmful chemicals (see table below). If the solution contacts your [e.g., skin, eyes, nose, or mouth], flush with larce amounts of water. If irritation persists, seek medical advice: https://www.ooisonhelp.org or 1-800-222-1222.

Chemical Name	GHS Code for Ingredients	Concentrations
Sodium Azide	H300, Acute Tox, Oral H310, Acute Tox, Dermal	0.09%

- Wear a safety mask or other face-covering when collecting a specimen from a child or another individual. Wear disposable gloves while handling kit reagents or specimens and thoroughly wash hands afterwards.
- 19. All specimens should be handled as if they are capable of transmitting disease. Observe established precautions against microbiological hazards throughout all procedures and follow the standard procedures for proper disposal of specimens and test devices.
- 20. If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, the specimen should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health departments for testing. Viral culture should not be attempted in these cases unless a BSL 3+ facility is available to receive and culture specimens.
- For more information on EUAs please visit: https://www.fda.gov/emergencypreparedness-and-response/mcm-legalregulatory-and-policyframework/emergencyuse-authorization.
- 22. For the most up to date information on COVID-19, please visit: www.cdc.gov/COVID19.

STORAGE AND STABILITY

ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test may be stored at 2-30°C (35-86°F) in the original sealed pouch, away from direct sunlight. Kit contents are stable until the expiration date printed on the pouch or box.

SPECIMEN COLLECTION AND PREPARATION

ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test can be performed on nasal and nasopharyngeal swabs. Use standard procedures for collecting a nasal or nasopharyngeal swab.

- Inadequate or inappropriate specimen collection, storage and transport are likely to yield false negative test results. Training in specimen collection is highly recommended because of the importance of specimen quality.
- To collect anterior nasal or nasopharyngeal swab specimens, only the swab provided in the ViraDx SARS-CoV-2/ Flu A+B Rapid Antigen Test kit should be used.
- Use fresh samples for best performance. Freshly collected specimens should be tested immediately. If necessary, swab samples can be stored for up to 4 hours at room temperature or up to 8 hours at 2-8°C.
- Transport media should not be used. This test has not been validated or authorized using viral transport media.

Specimen Collection Procedure

Good sample collection is the most important first step for an accurate test result. Therefore, carefully follow the instructions below for collection of anterior nasal or nasopharyngeal swab specimens to obtain as much secretion as possible.

To Collect Nasopharyngeal Swab Specimen

Use a flocked swab provided in the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test kit only. Tilt patient's head back 70 degrees. Gently and slowly insert a minitip swab with a flexible shaft through the nostril parallel to the palate (not upwards) until resistance is encountered or the distance is equivalent to that from the ear to the nostril of the patient, indicating contact with the nasopharynx. Swab should reach depth equal to distance from nostrils to outer opening of the ear. Gently rub and roll the swab. Leave swab in place for several seconds to absorb secretions. Slowly remove swab while rotating it. Specimens can be collected from both sides using the same swab, but it is not necessary to collect specimens from both sides if the minitip is saturated with fluid from the first collection. If a deviated septum or blockages create difficulty in obtaining the specimen from one nostril, use the same swab to obtain the specimen from the other nostril.



Nasopharyngeal Swab

To Collect Anterior Nasal Swab Specimen

Use a flocked swab provided in the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test kit only. Insert the entire soft end of the swab into the patient's nostril no more than $\frac{3}{4}$ of an inch (1.5 cm) into the patient's nose. Slowly rotate the swab, gently pressing against the inside of the patient's nostril at least 4 times for a total of 15 seconds. Get as much secretion as possible on the soft end of the swab. Gently remove the swab. Using the same swab, repeat in the second nostril with the same of the swab.




Anterior Nasal Swab

TEST PROCEDURE

Procedural Notes

- The test procedure below must be followed to obtain accurate and reproducible results.
- Reagents, specimens and devices must be at room temperature (18-30°C) for testing.
- Do not open the foil pouch until you are ready to perform the test.
- Label the device with the patient identification or control to be tested.
- Place test device on a level surface.



Tear the tab off the Extraction Reagent capsule and squeeze it to dispense all of the solution into the Extraction Tube. Insert the specimen swab into the Extraction Tube and rotate it 3 times to mix the specimen. Incubate for

1 minute with the swab in Extraction Tube. Rotate swab 3 times again to mix the specimen. Squeeze swab against the Extraction Tube to retain as much of the liquid as possible, then remove and discard the swab.

Place cap on Extraction Tube, invert and empty the entire contents of the Extraction tube onto the sample well of the test device.

Start timing – 15 minutes. Do not read test results before 15 minutes.

Note: False negative results can occur if the swab is not rotated as instructed below.

Note: To ensure proper test performance, it is important to read results at 15 minutes. False positive or false negative results can occur if the test is not read between 15 and 20 minutes.

INTERPRETATION OF RESULTS

Positive: Determination of a positive result is made at fifteen (15) minutes. A reddish purple Control line (C position) and a reddish purple Test line (A, B or S position) indicate that influenza A, B and/or SARS-CoV-2 antigen has been detected. Lines at the A and C positions indicate the presence of influenza type A viral antigen, lines at the B and C positions indicate the presence of influenza type B viral antigen, lines at the B and C positions indicate the presence of influenza type B viral antigen and lines at the S and C positions indicate the presence of influenza type B viral antigen co-infections with other pathogens or identify any specific influenza A virus subtype. Any faint visible reddish-purple lines at A, B, and S with control line (C) should be read as positive.

Repeat testing does not need to be performed if patients have a positive result at any time.

A positive S line test result means that the virus that causes COVID-19 was detected in the sample, and it is very likely the individual has COVID-19 and is contagious. Please contact the patient's doctor/primary care physician (if applicable) and the local health authority immediately and instruct your patient to adhere to the local guidelines regarding self-isolation. There is a very small chance that this test can give a positive result that is incorrect (a false positive).

Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Individuals who test positive with the ViraDx SARS-CoV-2//Flu A+B Rapid Antigen Test should self-isolate and seek follow up care with their physician or healthcare provider as additional confirmatory testing with a molecular test for positive results may also be necessary, if there is a low likelihood of COVID-19, such as in individuals without known exposures to COVID-19 or residing in communities with low prevalence of infection.

Note: The Test line (reddish purple line) may vary in shade and intensity (light or dark, weak or strong) depending on the concentration of antigen detected. The intensity of the Control line should not be compared to that of the Test line for the interpretation of the test result. Even a light or faint Test line should be interpreted as a positive result.

Negative: A reddish purple Control line (C position) only, with no Test line at the A, B, S positions, indicates that influenza A, B antigen or SARS-CoV-2 antigen has not been detected. A negative result does not exclude influenza viral or SARS-CoV-2 viral infection. Determination of negative results should not be made before 15 minutes.

To increase the chance that the negative result for COVID-19 is accurate, you should:

- Test again in 48 hours if the individual has symptoms on the first day of testing.
- Test 2 more times at least 48 hours apart if the individual does not have symptoms on the first day of testing. Negative


results are presumptive and may need to be confirmed with a molecular assay.

A negative test result indicates that the virus that causes COVID-19 and the influenza viruses were not detected in the sample. A negative result does not rule out COVID-19 and Influenza. There is a higher chance of false negative results with antigen tests compared to laboratory-based tests such as PCR tests. If the test is negative but COVID-19 and flu-like symptoms, e.g., fever, cough, and/or shortness of breath, continue, follow up testing for SARS-CoV-2 or influenza with a molecular test or testing for other respiratory disease should be considered. If applicable, seek follow up care with the primary health care provider.

All negative results should be treated as presumptive and confirmation with a molecular assay may be necessary if there is a high likelihood of SARS-CoV-2 infection, such as in an individual with a close contact with COVID-19 or with suspected exposure to COVID-19 or in communities with high prevalence of infection. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions.

Invalid: A reddish purple line should always appear at the Control line position (C position). If a line does not form at the Control line position in 15 minutes, the test result is invalid and the test should be repeated with a new ViraDx SARS-CoV-2/ Flu A+B Rapid Antigen Test device.

NOTE: Co-infection with influenza A, B and/or SARS-CoV-2 is rare. If results are positive for more than one antigen, i.e., influenza A, B and/or COVID-19, the patient specimens should be re-tested.



Repeat testing is needed to improve test accuracy. Please follow the table below when interpreting test results. Results should be considered in the context of an individual's recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19.

Status on First Day of Testing	Day 0	Day 2
g	(Test 1)	(Test 2)
	COVID-19 (-)	COVID-19 (-)
	Serial testing recommended for COVID	COVID result is Negative
	Flu A or B (-)	COVID-19 (+)
	Flu A or B result is negative	COVID result is positive
		Flu A or B (-)
		Flu result is Negative
		The result is regalive
		Flu A or B (+)
		Flu result is positive
	COVID-19 (-)	COVID-19 (-)
	Serial testing recommended for COVID	COVID-19 result is Negative
		COVID-19 (+)
	Flu A or B (+)	COVID-19 (1) COVID-19 result is Positive
With Symptoms	Flu A or B result is positive	
	·	Flu A or B (-)
		Maintain Flu positive interpretation
		Flu A or B (+) Flu A or B result is Positive
	COV/ID 40 (1)	
	COVID-19 (+) COVID Positive	No serial testing recommended
	COVID Positive	
	Flu A or B (-)	
	Flu A or B Negative	
	COVID-19 (+)	No serial testing recommended
	COVID Positive	
	Flu A or B (+) Flu A or B positive	
	I IU A OI D POSILIVE	

LIMITATIONS

- The performance of this test for SARS-CoV-2 was established based on the evaluation of a limited number of clinical specimens collected between September 2020 and April 2021 and February to November 2022. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.
- There is a higher chance of false negative results with antigen tests than with laboratory-based molecular tests due to the sensitivity of the test technology. This means that there is a higher chance this test will give a false negative result in an individual with COVID-19 as compared to a molecular test, especially in samples with low viral load.
- A negative test result does not exclude infection with SARS-CoV-2, influenza A or B. Negative test results are
- presumptive and may need to be confirmed with a molecular test. Therefore, the results obtained with ViraDx SARS- CoV-2/Flu A+B Rapid Antigen Test should be used in conjunction with clinical findings to make an accurate diagnosis. Additional testing is required to confirm the absence of infection, in consultation with state or local public health departments.
- If the patient continues to have symptoms of COVID-19, and both the patient's first and second tests are negative, the patient may not have COVID-19; however, additional follow-up may be needed.
- If the test is positive, then proteins from the virus that causes COVID-19 have been found in the sample, and the individual likely has COVID-19.
- This test detects both viable (live) and non-viable SARS-CoV-2, influenza A and B. Test performance depends on the amount of virus (antigen) in the specimen and may or may not correlate with viral culture or molecular assay results performed on the same specimen.
- A negative test result may occur if the level of antigen in a sample is below the detection limit of the test or if the sample was collected or transported improperly.
- Failure to follow the Test Procedure may adversely affect test performance and/or invalidate the test result.
- This test is read visually and has not been validated for use by those with impaired vision or color-impaired vision. Because test lines
 can be very faint, users with conditions affecting their vision- such as far-sightedness, glaucoma, or color blindness-are encouraged to
 seek assistance to interpret results accurately (e.g., reading glasses, additional light source, or another person).
- Positive test results do not rule out co-infections with other pathogens.
- Positive test results do not differentiate between SARS-CoV and SARS-CoV-2. Additional testing is needed if differentiation between SARS-CoV and SARS-CoV-2 is needed.
- Positive test results can distinguish among influenza A, B and SARS-CoV-2 viruses but do not differentiate specific influenza A virus subtypes.
- If differentiation of specific SARS or influenza A subtypes and strains is needed, additional testing, in consultation with state or local public health departments, is required.
- ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test uses highly target epitope specific monoclonal antibodies. As in most immunoassays, it may fail to detect, or detect with less sensitivity, influenza A viruses that have undergone minor amino acid changes in the target epitope region.
- Performance of the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test has not been established for monitoring antiviral treatment of influenza and SARS-CoV-2.
- Performance characteristics for influenza A were established when influenza A/H3 and A/H1 were the predominant influenza A viruses in circulation. When other influenza A viruses emerge, performance characteristics may vary.
- The performance of this test has not been evaluated for use in patients without signs and symptoms of respiratory infection.
- The performance of this test has not been evaluated for specimen types other than those specified in the Intended Use.
- The performance of this test has not been evaluated for immunocompromised individuals.
- The performance of ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test was not evaluated for SARS-CoV-2 detection with samples
 collected in viral transport media and should not be used with this test.
- Children tend to shed influenza virus more abundantly and for longer periods of time than adults. Therefore, testing specimens from adults will result in lower sensitivity than testing specimens from children.
- Positive and negative predictive values are highly dependent on prevalence. False negative test results are more likely during peak
 activity when prevalence of disease is high. False positive test results are more likely during periods of low activity when prevalence is
 moderate to low.
- Individuals who received nasally administered influenza A vaccine may produce positive test results for up to three days after vaccination.

USER QUALITY CONTROL

Internal Quality Control

Each ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test device has built-in controls. The Control line at the C position can be considered as an internal positive procedural control; i.e., a proper amount of sample was used, sample was properly added to the Sample Well, sample migrated properly and the reagent system worked properly. A distinct reddish-purple Control line should always appear if the test has been performed correctly. If the Control line does not appear, the test result is invalid and a new test should be performed. If the problem persists, contact Lumos Diagnostics Technical Support at 1.855.LumosDx or 1.855.568.6739 for technical assistance. A clear background in the Test Result Window is considered an internal negative procedural control. If the test is performed correctly and the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test device is working properly, the background in the Test Result Window will be clear, providing a distinct result.

External Quality Control

Good laboratory practice includes the use of external controls to ensure proper kit performance. It is recommended that external control testing be performed by each new operator and before using a new lot or shipment of ViraDx SARS- CoV-2/Flu A+B Rapid Antigen Test kits to confirm the expected test performance, using the external controls provided in the kit. The frequency of additional Q.C. tests should be determined according to your laboratory's standard Q.C. procedures and local, state and federal regulations or accreditation requirements. Upon confirmation of the expected results, the kit is ready for use with patient specimens. If external controls do not perform as expected, do not use the test results, do not report patient results. Repeat the test or contact Lumos Diagnostics Technical Support. The built-in reddish purple Control line indicates only the integrity of the test device and proper fluid flow but does not control integrity of the analyte specific test reagents.

The ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test kit therefore contains two external Control Swabs. Test the Control Swabs in the same manner as patient specimens. When the positive control is tested, reddish purple lines appear at the C as well as A, B and S positions. When the Negative Control Swab is tested, a reddish purple line appears at the C position only.

The use of positive and negative controls from other commercial kits has not been established with ViraDx SARS-CoV-2/ Flu A+B Rapid Antigen Test.

EXPECTED VALUES

The rate of positive results for COVID-19, influenza A and B in individuals with symptoms of respiratory illness varies depending on many factors, including the specimen collection method, the disease prevalence, and the geographic location. The prevalence of influenza varies every year and the rate of positives in influenza testing varies depending on many factors, including the specimen collection method, the test method used, the disease prevalence and the geographic location. The expected values based on previous Status Flu A&B results are 30.3% for influenza A and 13.8% for influenza B during the 2007-2009 prospective clinical study, and were 33.6% for influenza A and 9.8% for influenza B during the 2014-2016 prospective clinical study.

CONDITIONS OF AUTHORIZATION FOR THE LABORATORY AND PATIENT CARE SETTINGS

ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients and authorized labeling are available on the FDA website:

https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical- devices/in-vitro-diagnostics-euas

However, to assist in using ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test ("your product" in the conditions below), the relevant Conditions of Authorization are listed below:

- Authorized laboratories* using your product must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using your product must use your product as outlined in the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test Instructions for Use and Quick Reference Instructions. Deviations from the authorized procedures, including the authorized instruments, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.
- Authorized laboratories that receive your product must notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- Authorized laboratories using your product must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- Authorized laboratories must collect information on the performance of your product and report to DMD/OHT7- OIR/ OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) or Lumos Diagnostics (via phone at 1.855.LumosDx,1.855.568.6739 or email technical.support@lumosdiagnostics.com) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your product of which they become aware.

^{*}The letter of authorization refers to, "Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high, moderate or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation."

- All operators using your product must be appropriately trained in performing and interpreting the results of your product, use appropriate personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.
- Princeton BioMeditech Corp., authorized distributors, and authorized laboratories using your product must ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

PERFORMANCE CHARACTERISTICS

Clinical Performance - Nasopharyngeal Swab Specimen

The clinical study was performed using the Status COVID-19/Flu A&B, which uses the same test kit components (e.g., buffer, antibodies) but differs in the design of the plastic cassette housing (See "Principle of Procedure" for more information). A prospective study was performed in which two hundred eighteen (218) direct nasopharyngeal swabs were sequentially enrolled (between September 2020 and April 2021) and tested fresh. The samples were collected from symptomatic patients suspected of infection with COVID-19, at five Point of Care (POC) CLIA waived clinical sites. To be enrolled in the study, patients had to present at the participating study site with signs and symptoms of respiratory infection generally observed from SARS-CoV-2, influenza A and/or influenza B, during the study period. Patients presenting within five (5) days of symptom onset were included in the study. The nasopharyngeal swab specimens were collected from each patient; one swab specimen to be tested using a comparator method, an FDA Emergency Use Authorized RT-PCR assay for the detection of SARS-CoV-2 and Flu A and B, and the other swab specimen to be tested at the study site.

SARS-CoV-2 Performance Patient Demographics

Patient demographics (age, the elapsed time from date of symptom onset) are available for the 218 patients participating in this study. COVID-19 Positive results are broken down by age and days post symptom onset in the tables below.

A.co			
Age	Total	# COVID-	Prevalence
		19 Positive	
≤ 5 years	16	1	6.3%
6 to 21 years ^a	68	10	14.7%
22 to 59 years ^b	109	37	33.9%
≥ 60 years°	24	6	25.0%
Unknown ^d	1	0	N/A

Patient Demographics (COVID-19 positive = 54)

a. One patient was antigen test negative and positive by reference extracted RT-PCR.

b. One patient was antigen test negative and positive by reference extracted RT-PCR.

c. Two patients were antigen test negative and positive by reference extracted RT-PCR.

d. One patient did not provide age information.

Specimen Positivity Breakdown Based On Days Post Onset (COVID-19 positive = 54)

Days Post Symptom			
Onset	Total # Tested	# COVID-19 Positive	% Positive
Oe	38	8	21.1%
1	71	5	7.0%
2	59	16	27.1%
3	25	13	52.0%
4	12	6	50.0%
5 ^f	13	6	46.2%

e. Three specimens were antigen test negative and positive by reference extracted RT-PCR.

f. One specimen was antigen test negative and positive by reference extracted RT-PCR.

Summary of clinical performance compared to reference PCR: COVID-19 (SARS-CoV-2)

		Reference Extracted RT-PCR: SARS-CoV-2			Performance
		Positive	Negative	Total	(95% CI)
Status COVID- 19 /Flu A&B	SARS-CoV-2 Positive	54	0	54	Sensitivity: 93.1% 95% CI: 83.6% to 97.3%
	SARS-CoV-2 Negative	4	160	164	Specificity: 100% 95% Cl: 97.7% to 100.0%
To	tal	58	160	218	

Summary of clinical performance compared to reference PCR: Influenza A

		Reference Extracted RT-PCR: Influenza A			Performance
		Positive	Negative	Total	(95% CI)
Status COVID- 19 /Flu A&B	Influenza A Positive	0	0	0	NA
	Influenza A Negative	0	218	218	NPA: 100% 95% CI: 98.3% to 100.0%
To	tal	0	218	218	

Summary of clinical performance compared to reference PCR: Influenza B

	Reference Extracted RT-PCR: Influenza B		Reference Extracted RT-PCR: Influenza B		Performance
		Positive	Negative	Total	(95% CI)
Status COVID- 19 /Flu A&B	Influenza B Positive	0	0	0	NA
	Influenza B Negative	0	218	218	NPA: 100% 95% CI: 98.3% to 100.0%
То	tal	0	218	218	

Clinical Performance - Anterior nasal swab specimen

The clinical study was performed using the Status COVID-19/Flu A&B, which uses the same test kit components (e.g., buffer, antibodies) but differs in the design of the plastic cassette housing (See "Principle of Procedure" for more information). A prospective study was performed in which one hundred ninety-three (193) direct anterior nasal swab specimens were sequentially enrolled (between September 2020 and April 2021) and tested fresh. The samples were collected from symptomatic patients suspected of infection with COVID-19, at five Point of Care (POC) CLIA waived clinical sites. To be enrolled in the study, patients had to present at the participating study site with signs and symptoms of respiratory infection generally observed from SARS-CoV-2, influenza A and/or influenza B, during the study period. Patients presenting within five (5) days of symptom onset were included in the study. One nasopharyngeal swab specimen and one anterior nasal swab specimen were collected from each patient; one nasopharyngeal swab to be tested using a comparator method, an FDA Emergency Use Authorized RT-PCR assay for the detection of SARS-CoV-2 and influenza A and B and one anterior nasal swab specimen to be tested at the study site.

SARS-CoV-2 Performance Patient Demographics

Patient demographics (age, the elapsed time from date of symptom onset) are available for the 193 patients participating in this study. COVID-19 Positive results are broken down by age and days post symptom onset in the tables below.

Patient Demographics (COVID-19 positive = 45)

٨			
Age	Total	# COVID-19 Positive	Prevalence
≤ 5 years	16	1	6.3%
6 to 21 years ^a	65	9	13.8%
22 to 59 years ^b	94	31	33.0%
≥60 years°	18	4	22.2%

a. One patient was antigen test negative and positive by reference extracted RT-PCR.

b. One patient was antigen test negative and positive by reference extracted RT-PCR.

c. Two patients were antigen test negative and positive by reference extracted RT-PCR.

Specimen Positivity Breakdown Based On Days Post Onset (COVID-19 positive = 45)

Days Post Symptom			
Days Post Symptom Onset	Total # Tested	# COVID-19 Positive	% Positive
0 ^d	32	5	15.6%
1	70	4	5.7%
2	53	15	28.3%
3	21	11	52.4%
4	7	4	57.1%
5	10	6	60.0%

d. Three specimens were antigen test negative and positive by reference extracted RT-PCR.

Summary of clinical performance compared to reference PCR: COVID-19 (SARS-CoV-2)

		Reference Extracted RT-PCR: SARS-CoV-2			Performance
		Positive	Negative	Total (95% CI)	
Status COVID-19 /Flu A&B	SARS-CoV- 2 Positive	45	0	45	Sensitivity: 93.8% 95% Cl: 83.2% to 97.9%
	SARS-CoV-2 Negative	3	145	148	Specificity: 100% 95% CI: 97.4% to 100.0%
Tot	al	48	145	193	

		Reference Extracted RT-PCR: Influenza A		Influenza A	Performance
		Positive	Negative	Total	(95% CI)
Status COVID-19 /Flu A&B	Influenza A Positive	0	0	0	NA
	Influenza A Negative	0	193	193	NPA: 100% 95% Cl: 98.1% to 100.0%
Tot	al	0	193	193	

Summary of clinical performance compared to reference PCR: Influenza B

		Reference Extracted RT-PCR: Influenza B			Performance
		Positive	Negative	Total	(95% CI)
Status COVID-19 /Flu A&B	Influenza B Positive	0	0	0	NA
	Influenza B Negative	0	193	193	NPA: 100% 95% CI: 98.1% to 100.0%
Total		0	193	193	

Clinical Performance – Anterior nasal swab specimens vs Anterior nasal swab specimens for comparator method The clinical study was performed using the Status COVID-19/Flu A&B, which uses the same test kit components (e.g., buffer, antibodies) but differs in the design of the plastic cassette housing (See "Principle of Procedure" for more information). A prospective study was performed in which one hundred four (104) direct anterior nasal swab specimens were sequentially enrolled (between February and November 2022) and tested fresh. The samples were collected from symptomatic patients suspected of infection with COVID-19, at four Point of Care (POC) CLIA waived clinical sites. To be enrolled in the study, patients had to present at the participating study site within five (5) days of symptom onset with signs and symptoms of respiratory infection generally observed from SARS-CoV-2, influenza A and/or influenza B, during the study period. Two anterior nasal swab specimens were collected from each patient; one swab was tested using the comparator method, and the other swab to be tested with the Status COVID-19/Flu A&B.

SARS-CoV-2 Performance

Patient Demographics

Patient demographics (age, the elapsed time from date of symptom onset) are available for the 104 patients participating in this study. COVID-19 and Flu Positive results are broken down by age and days post symptom onset in the tables below. Patient Demographics (COVID-19 positive = 12; Flu A positive = 54)

Age			
	Total	# COVID-19 Positive	Prevalence
≤ 5 years	6	0	NA
6 to 21 years	42	4	9.5%
22 to 59 years ¹⁾	45	3	6.7%
≥60 years	11	4	36.4%

1) One patient was antigen test negative and positive by reference extracted RT-PCR.

Specimen Positivity Breakdown Based On Days Post Onset (COVID-19 positive = 11; Flu A positive = 54)

Days Post Symptom Onset			
	Total # Tested	# COVID-19 Positive	% Positive
O ¹⁾	20	1	5.0%
1	32	4	12.5%
2	31	2	6.5%
3	14	2	14.3%
4	4	2	50.0%
5	3	0	NA

1) One patient was antigen test negative and positive by reference extracted RT-PCR.

Summary of clinical performance compared to reference PCR: COVID-19 (SARS-CoV-2)

		Reference E	xtracted RT-PCR:	SARS-CoV-2	Performance (95% CI)
		Positive	Negative	Total	
Status COVID-19 /Flu A&B	SARS-CoV-2 Positive	11	0	11	Sensitivity: 91.7% 95% CI: 64.6% to 98.5%
	SARS-CoV-2 Negative	1	92	93	Specificity: 100% 95% CI: 96.0% to 100.0%
Total		12	92	104	

Influenza A Performance

Summary of clinical performance compared to reference PCR: Influenza A

		Reference	Extracted RT-PCR:	Influenza A	Performance (95% CI)
		Positive	Negative	Total	
Status COVID-19 /Flu A&B	Influenza A Positive	54	0	54	Sensitivity: 94.7% 95% CI: 85.6% to 98.2%
	Influenza A Negative	3	47	50	Specificity: 100% 95% CI: 92.4% to 100.0%
Total		57	47	104	

Influenza B Performance

Summary of clinical performance compared to reference PCR: Influenza B

		Reference I	Extracted RT-PCR:	Influenza B	Performance (95% CI)
		Positive	Negative	Total	
Status COVID-19 /Flu A&B	Influenza B Positive	0	0	0	NA
	Influenza B Negative	0	104	104	NPA: 100% 95% CI: 98.1% to 100.0%
Total		0	104	104	

Serial Testing for SARS-CoV-2

A prospective clinical study was conducted between January 2021 and May 2022 as a component of the Rapid Acceleration of Diagnostics (RADx) initiative from the National Institutes of Health (NIH). A total of 7,361 individuals were enrolled via a decentralized clinical study design, with a broad geographical representation of the United States. Per inclusion criteria, all individuals were asymptomatic upon enrollment in the study and at least 14 days prior to it and did not have a SARS-CoV-2 infection in the three months prior to enrollment. Participants were assigned to one of three EUA authorized SARS-CoV-2 OTC rapid antigen tests to conduct serial testing (every 48 hours) for 15 days. If an antigen test was positive, the serial-antigen testing result is considered positive.

At each rapid antigen testing time point, study subjects also collected a nasal swab for comparator testing using a home collection kit (using a 15-minute normalization window between swabs). SARS-CoV-2 infection status was determined by a composite comparator method on the day of the first antigen test, using at least two highly sensitive EUA RT-PCRs. If results of the first two molecular test were discordant a third highly sensitive EUA RT-PCR test was performed, and the final test result was based upon the majority rule.

Study participants reported symptom status throughout the study using the MyDataHelps app. Two-day serial antigen testing is defined as performing two antigen tests 36 – 48 hours apart. Three-day serial antigen testing is defined as performing three antigen tests over five days with at least 48 hours between each test.

Out of the 7,361 participants enrolled in the study, 5,609 were eligible for analysis. Among eligible participants, 154 tested positive for SARS-CoV-2 infection based on RT-PCR, of which 97 (62%) were asymptomatic on the first day of their infection, whereas 57 (39%) reported symptoms on the first day of infection. Pre-symptomatic subjects were included in the positive percent agreement (PPA) of asymptomatic individuals, if they were asymptomatic on the first day of antigen testing, regardless of whether they developed symptoms at any time after the first day of testing. Performance of the antigen test with serial testing in individuals is described in Table below.

Data establishing PPA of COVID-19 antigen serial testing compared to the molecular comparator single day testing throughout the course of infection with serial testing. Data is from all antigen tests in study combined.

DAYS AFTER FIRST PCR POSITIVE TEST RESULT	ASYMPTOMATIC ON FIRST DAY OF TESTING			SYMPTOMATIC ON FIRST DAY OF TESTING				
			Ag Positive (Antigen Test Perf	/ PCR Positive formance % PPA)				
	1 Test	2 Tests	3 Tests	1 Test	2 Tests	3 Tests		
0	9/97	35/89	44/78	34/57	47/51	44/47		
U	(9.3%)	(39.3%)	(56.4%)	(59.6%)	(92.2%)	(93.6%)		
2	17/34	23/34	25/32	58/62	59/60	43/43		
2	(50.0%)	(67.6%)	(78.1%)	(93.5%)	(98.3%)	(100%)		
4	16/21	15/20	13/15	55/58	53/54	39/40		
4	(76.2%)	(75.0%)	(86.7%)	(94.8%)	(98.1%)	(97.5%)		
6	20/28	21/27	16/18	27/34	26/33	22/27		
Ū	(71.4%)	(77.8%)	(88.9%)	(79.4%)	(78.8%)	(81.5%)		
8	13/23	13/22	4/11	12/17	12/17	7/11		
Ū	(56.5%)	(59.1%)	(36.4%)	(70.6%)	(70.6%)	(63.6%)		
10	5/9	5/8		4/9	3/7			
10	(55.6%)	(62.5%)		(44.4%)	(42.9%)			

1 Test = one (1) test performed on the noted days after first PCR positive test result. Day 0 is the first day of documented infection with SARS-CoV-2.

2 Tests = two (2) tests performed an average of 48 hours apart. The first test performed on the indicated day and the second test performed 48 hours later.

3 Tests = three (3) tests performance an average of 48 hours apart. The first test performed on the indicated day, the second test performed 48 hours later, and a final test performed 48 hours after the second test.

Influenza A and B Performance

ViraDx SARS-CoV-2//Flu A+B Rapid Antigen Test is a lateral flow immunoassay intended to aid in the rapid differential diagnosis of influenza A, B and COVID-19 viral infections. It is a modification of the test device used in the FDA-cleared Status Flu A&B and BioSign Flu A+B (K182157) to include addition of monoclonal antibodies for the detection of SARS-CoV-2 and modification of the test design (See "Principle of Procedure" for more information). Data for the detection of influenza A and B by the Status Flu A&B test are presented below.

Prospective Clinical Study from 2007 to 2009

A prospective clinical study was conducted from January 2007 to March 2008 and during March and April 2009 to determine the performance of Status Flu A&B for nasopharyngeal swab specimens.

The samples were collected at 5 sites in the USA from patients who visited physicians' offices and clinics with signs and symptoms of respiratory infection during the study period. Collected samples were tested with the Status Flu A&B, and results were compared to an FDA-cleared RT-PCR comparator assay.

The total number of patients tested was 862, of which 30% were 5 and younger, 38% were 6-21 years old, and the rest were older than 21. Forty-eight (48) percent were male and 52% were female. Performance of the Status Flu A&B against the PCR comparator assay for all nasopharyngeal and anterior nasal swab samples are presented in the tables below.

		PCR Results	6			F	PCR Results	6	
Status Flu A&B	Flu A Positive	Flu A Negative	Total	Performance	<i>Status</i> Flu A&B	Flu B Positive	Flu B Negative	Total	Performance
Flu A Positive	165	25	190	Sensitivity: 92.2% 95% Cl: 87.3-95.3%	Flu B Positive	72	30	102	Sensitivity: 90.0% 95% Cl: 81.5-94.8%
Flu A Negative	14	405	419	Specificity: 94.2% 95% CI: 91.6-96.0%	Flu B Negative	8	499	507	Specificity: 94.3% 95% CI: 92.0-96.0%
Total	179	430	609		Total	80	529	609	

Nasopharyngeal and Anterior Nasal Swab Samples (combined): Comparison with PCR Prospective Clinical Study from 2014 to 2016

An additional prospective clinical study was conducted from December 2014 to May 2016 to evaluate the performance of Status Flu A&B for nasopharyngeal and anterior nasal swab specimens when used by operators at CLIA-waived sites. The nasopharyngeal and anterior nasal swab specimens were collected at 7 CLIA waived sites in the USA from patients with signs and symptoms of respiratory infection during the study period. All collected samples were tested with both the Status Flu A&B and the PCR comparator assay. The total number of patients tested prospectively in this clinical study was 307, of which 37% were 5 and younger, 50% were 6-21 years old, and the rest were older than 21. Forty-nine (49) percent were male and 51% were female.

The data showing the performance of the Status Flu A&B assay against the PCR comparator assay for all the prospectively collected and tested swab samples from 2014 to 2016 are presented in the tables below.

	PCR Results		PCR Results			F	PCR Results			
Status Flu A&B	Flu A Positive	Flu A Negative	Total	Performance		<i>Status</i> Flu A&B	Flu B Positive	Flu B Negative	Total	Performance
Flu A Positive	101	2	103	Sensitivity: 90.2% 95% Cl: 83.3-94.4%		Flu B Positive	27	3	30	Sensitivity: 81.8% 95% CI: 65.6-91.4%
Flu A Negative	11	193	204	Specificity: 99.0% 95% Cl: 96.3-99.7%		Flu B Negative	6	271	277	Specificity: 98.9% 95% CI: 96.8-99.6%
Total	112	195	307			Total	33	274	307	

ANALYTICAL PERFORMANCE

Limit of Detection (LOD)

Limit of detection (LOD) for SARS-CoV-2 and influenza A and B in ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test was determined by evaluating different concentrations of heat inactivated viruses. The viruses were diluted in negative nasal wash (NSW) to generate virus dilutions for testing. Nasopharyngeal swab samples were prepared by adding 50µL of each virus dilution onto the sterile swab. Test swab samples were prepared by adding 50µL of each virus dilution onto the sterile swab. The swab samples were tested according to the test procedure in package insert. Results showed equivalence to the Status™ COVID-19/Flu A&B test.

Virus Strains	Sources	LoD	LoD/Swab	#Positive/ #Total	% Positive
SARS-COV-2 USA-WA1/2020	Zeptometrix, Cat#, 0810587CFHI	2.87 x 10 ³ TCID₅₀/mL	1.44 x 10 ²	20/20	100
Influenza A A/California/07/09(H1N1)	Zeptometrix, Cat# 0810165CF	6.90 x 10 ³ TCID ₅₀ /mL	3.45 x 10 ²	57/60	95
Influenza A Victoria/361/11(H3N2)	Zeptometrix, Cat# 0810240CF	1.90 x 10 ³ TCID ₅₀ /mL	9.50 x 10 ¹	19/20	95
Influenza B Victoria/504/00	Zeptometrix, Cat# 0810571CF	3.15 x 10 ³ TCID ₅₀ /mL	1.58 x 10 ²	20/20	100
Influenza B Yamagata/16/88	Zeptometrix, Cat# 0810518CF	3.53 x 10 ² TCID₅₀/mL	1.77 x 10 ¹	19/20	95

WHO Standard testing

The LoD of SARS-CoV-2 with the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test was determined by using different dilutions of WHO International Standard for SARS-CoV-2 antigen (NIBS code:21/369) in pooled negative nasal swab matrix. 50µl were pipetted onto each swab and swabs were processed per the IFU. The LoD was determined as the lowest virus concentration that was detected ≥95% of the time (i.e., concentration at which at least 19 out of 20 replicates tested positive).

WHO Internationa	al Standard	l	_oD
		IU/mL	IU/Swab
SARS-CoV-2 antigen	NIBSC code: 21/368	1 x 10 ³	50

Analytical Reactivity/Inclusivity

The analytical reactivity of the monoclonal antibodies targeting SARS-CoV-2 in ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test were evaluated with the currently available SARS-CoV-2 Strains.

2019-nCoV Strain/ Isolate	Source/Type	Analytical Reactivity	
USA-WA1/2020	Zeptometrix Cat# 0810587CFHI/NR-52281	3.68 x10 ³ TCID∞/mL	
Hong Kong/VM20001061/2020	Zeptometrix Cat# 0810590CFHI/NR-52282	3.68 x10 ³ TCID ₅₀ /mL	
Italy-INMI1	Zeptometrix Cat# 0810589CFHI/NR-52284	6.52 x10 ³ TCID ₅₀ /mL	

The 2023 CDC Human Influenza Panel was tested with *Status* Flu A&B test. The panel was tested as per the swab protocol recommended by the CDC. Briefly, a series of 5-fold dilutions were prepared with each panel. These dilutions were tested in five replicates until two consecutive dilutions were negative. Test results are tabulated next.

CDC human influenza virus A panel (VP2023) test result (swab sample)

Influenza Virus (Type/Subtype)	Virus Strain Name	a	Virus Serial Dilution Concentration (EID50/mL) and Number of Positive Results at Each Dilution (no. of positives /5 replicates)					
A(H1N1)pdm09	A/Victoria/489	10 ^{8.5}	2x10 ^{7.5}	4x10 ^{6.5}	8x10 ^{5.5}	1.6x10 ^{5.5}	3.2x10 ^{4.5}	n/a
A(ITTAT)patilos	7/2022	n/a	5/5	5/5	2/5	0/5	0/5	n/a
A(H1N1)pdm09	A(H1N1)pdm09 A/Victoria/257	10 ^{8.3}	2x10 ^{7.3}	4x10 ^{6.3}	8x10 ^{5.3}	1.6x10 ^{5.3}	3.2x10 ^{4.3}	n/a
A(ITTAT)patilos	0/2019	n/a	5/5	5/5	3/5	0/5	0/5	n/a
A(H3N2)	A/Darwin/9/20	10 ^{8.3}	2x10 ^{7.3}	4x10 ^{6.3}	8x10 ^{5.3}	1.6x10 ^{5.3}	3.2x10 ^{4.3}	6.4x10 ^{3.3}
A(H3NZ)	21	n/a	5/5	5/5	5/5	5/5	0/5	0/5
A(H3N2) A/Georgia/02/ 2022	A/Georgia/02/	10 ^{9.5}	2x10 ^{8.5}	4x10 ^{7.5}	8x10 ^{6.5}	1.6x10 ^{6.5}	3.2x10 ^{5.5}	n/a
		n/a	5/5	5/5	5/5	0/5	0/5	n/a

CDC human influenza virus B panel (VP2023) test result (swab sample)

Influenza Virus (Type/Su btype)	Virus Strain Name		Virus Serial Dilution Concentration (EID50/mL) and Number of Positive Results at Each Dilution (no. of positives /5 replicates)						
B	B/Austria/1	10 ^{8.5}	2x10 ^{7.5}	4x10 ^{6.5}	8x10 ^{5.5}	1.6x10 ^{5.5}	3.2x10 ^{4.5}	n/a	n/a
(Victoria lineage)	359417/202 1	n/a	5/5	5/5	1/5	0/5	0/5	n/a	n/a
B (Victoria		10 ^{8.7}	2x10 ^{7.7}	4x10 ^{6.7}	8x10 ^{5.7}	1.6x 10 ^{5.7}	3.2x10 ^{4.7}	n/a	n/a
lineage)	ds/10894/2 0 22	n/a	5/5	5/5	5/5	0/5	0/5	n/a	n/a
B	B/Phuket/3	10 ^{7.8}	2x10 ^{6.8}	4x10 ^{5.8}	8x10 ^{4.8}	1.6x10 ^{4.8}	3.2x10 ^{3.8}	n/a	n/a
(Yamag ata lineage)	073/2013	n/a	5/5	5/5	5/5	0/5	0/5	n/a	n/a
B (Yamag ata lineage) B/Norway/2 134/2019	10 ^{9.5}	2x10 ^{8.5}	4x10 ^{7.5}	8x10 ^{6.5}	1.6x10 ^{6.5}	3.2x10 ^{5.5}	6.4x10 ^{4.5}	1.28x10 ^{4.5}	
	n/a	5/5	5/5	5/5	5/5	2/5	0/5	0/5	

The analytical inclusivity for influenza A and B was demonstrated with Status Flu A&B using a total of 49 influenza strains: 34 strains of influenza A type and 15 strains of influenza B type. Additional information detailing this testing can be found in Status Flu A&B package insert.

The performance of this test device in the detection of the Omicron variant of SARS-CoV-2 was evaluated in a dilution series of clinical specimens which were positive for the Omicron variant. This testing was conducted by the National Institutes of Health (NIH) as a component of the Rapid Acceleration of Diagnostics (RADx®) initiative. The clinical specimens used to prepare this dilution series were not identical to the previous specimen pools prepared and tested by RADx to assess performance with the Omicron variant. Results from this dilution series cannot be compared to other specimen pools and do not indicate that a test will have different clinical performance compared to other EUA authorized tests. Compared to an EUA authorized RT-PCR method, the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test detected 100% of live virus Omicron samples at a Ct-value of 29.2 (n=5). Testing was also compared to two additional EUA authorized OTC antigen tests (Assay #1 and Assay #2). Omicron dilutions at lower viral concentrations (Ct-values greater than 29.2) were not detected by the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test in this study.

Omicron Pool 1 – Live Omicron Clinical Samples	Average N2 Ct (n=9)	Assay #1 Percent Positive (n=5)	Assay #2 Percent Positive (n=5)	ViraDx SARS-CoV-2/ Flu A+B Rapid Antigen Test Percent Positive (n=5)
Omicron Dilution 1	20.6	100	100	100
Omicron Dilution 2	21.5	100	100	100
Omicron Dilution 3	22.7	100	100	100
Omicron Dilution 4	24.0	100	100	100
Omicron Dilution 5	25.3	100	100	100
Omicron Dilution 6	26.0	100	100	100
Omicron Dilution 7	27.3	0	60	100
Omicron Dilution 8	28.8	0	0	100
Omicron Dilution 9	29.2	0	0	100
Omicron Dilution 10	30.6	0	0	0
Omicron Dilution 11	31.7	0	0	0
Omicron Dilution 12	32.6	0	0	0

Analytical Specificity (Cross-reactivity)

Cross-reactivity of ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test was evaluated by testing a panel of related pathogens, high prevalence disease agents, and normal or pathogenic flora that are reasonably likely to be encountered in clinical specimens and could potentially cross-react with ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test including ten (10) bacteria, eighteen (18) viruses and one (1) negative matrix. Each organism and virus were tested in the absence or presence of heat inactivated SARS-CoV-2, influenza A, and B at 3 x LoD. No cross-reactivity was seen with the listed microorganisms when tested at the concentration presented in the table below.

Cross-Reactivity SARS-CoV-2

Potential Cross-Reactant	Concentration Tested	
Human coronavirus 229E	1.0 x 10 ⁵ TCID ₅₀ /mL	
Human coronavirus OC43	1.0 x 10 ⁵ TCID ₅₀ /mL	
Human coronavirus NL63	1.0 x 10 ⁵ TCID ₅₀ /mL	
Adenovirus C1	1.0 x 10 ⁵ TCID ₅₀ /mL	
Human Metapneumovirus(hMPV)	1.0 x 10 ⁵ TCID ₅₀ /mL	
Parainfluenza virus 1, C35	1.0 x 10 ⁵ TCID ₅₀ /mL	
Parainfluenza virus 2, Greer	1.0 x 10 ⁵ TCID ₅₀ /mL	
Parainfluenza virus 3, C243	1.0 x 10 ⁵ TCID ₅₀ /mL	
Parainfluenza virus 4, CH19503	1.0 x 10 ⁵ TCID ₅₀ /mL	
Influenza A A/California/2/2014(H3N2)	1.0 x 10 ⁵ TCID ₅₀ /mL	
Influenza A A/Hong Kong/8/68(H3N2)	1.0 x 10 ⁵ TCID ₅₀ /mL	
Influenza A A/California/07/2009(H1N1)	1.0 x 10 ⁵ CEID ₅₀ /mL	
Influenza B B/Russia/69	1.0 x 10 ⁵ CEID ₅₀ /mL	
Influenza B B/Florida/02/06	1.0 x 10 ⁵ TCID ₅₀ /mL	
Human enterovirus 71Strain: H	1.0 x 10 ⁵ TCID ₅₀ /mL	
Human respiratory syncytial virus, A2	1.0 x 10 ⁵ PFU/mL	
Rhinovirus 2060	1.0 x 10 ⁵ PFU/mL	
Haemophilus influenza	$1.0 \times 10^{\circ}$ cfu/mL	
Streptococcus pneumoniae	1.0 x 10 ⁶ cfu/mL	
Streptococcus pyogenes, Bruno	4.0 x 10 ⁶ cfu/mL	
Candida albicans	1.0 x 10 ⁶ cfu/mL	
Bordetella pertussis, 18323	1.0 x 10 ⁶ cfu/mL	
Mycoplasma pneumoniae	1.0 x 10 ⁶ cfu/mL	
Chlamydia pneumoniae TW-183	1.0 x 10 ⁶ IFU/mL	
Legionella pneumophila	1.0 x 10 ⁶ cfu/mL	
Pneumocystis jirovecii	1.0 x 10 ⁶ cfu/mL	
Staphylococcus epidermidis	1.0×10^{6} cfu/mL	
Staphylococcus aureus	1.0 x 10 ⁶ cfu/mL	
Pooled human nasal wash	NA	

Potential Cross-Reactant	Concentration Tested
Human coronavirus 229E	1.0 x 10 ⁵ TCID ₅₀ /mL
Human coronavirus OC43	1.0 x 10 ⁵ TCID ₅₀ /mL
Human coronavirus NL63	1.0 x 10 ⁵ TCID ₅₀ /mL
Adenovirus C1	1.0 x 10 ⁵ TCID ₅₀ /mL
Human Metapneumovirus(hMPV)	1.0 x 10 ⁵ TCID ₅₀ /mL
Parainfluenza virus 1, C35	1.0 x 10 ⁵ TCID ₅₀ /mL
Parainfluenza virus 2, Greer	1.0 x 10 ⁵ TCID ₅₀ /mL
Parainfluenza virus 3, C243	1.0 x 10 ⁵ TCID ₅₀ /mL
Parainfluenza virus 4, CH19503	1.0 x 10 ⁵ TCID ₅₀ /mL
Influenza B B/Russia/69	1.0 x 10 ⁵ CEID ₅₀ /mL
Influenza B B/Florida/02/06	1.0 x 10 ⁵ TCID ₅₀ /mL
Human enterovirus 71Strain: H	1.0 x 10 ⁵ TCID ₅₀ /mL
Human respiratory syncytial virus, A2	1.0 x 10 ⁵ PFU/mL
Rhinovirus 2060	1.0 x 10 ⁵ PFU/mL
Haemophilus influenza	1.0 x 10 ⁶ cfu/mL
Streptococcus pneumoniae	1.0 x 10 ⁶ cfu/mL
Streptococcus pyogenes, Bruno	4.0 x 10 ⁶ cfu/mL
Candida albicans	1.0 x 10 ⁶ cfu/mL
Bordetella pertussis, 18323	1.0 x 10 ⁶ cfu/mL
Mycoplasma pneumoniae	1.0 x 10 ⁶ cfu/mL
Chlamydia pneumoniae TW-183	1.0 x 10 ⁶ IFU/mL
Legionella pneumophila	1.0 x 10 ⁶ cfu/mL
Pneumocystis jirovecii	1.0 x 10 ⁶ cfu/mL
Staphylococcus epidermidis	1.0 x 10 ⁶ cfu/mL
Staphylococcus aureus	1.0 x 10 ⁶ cfu/mL
Pooled human nasal wash	NA

Potential Cross-Reactant	Concentration Tested
Human coronavirus 229E	1.0 x 10 ⁵ TCID ₅₀ /mL
Human coronavirus OC43	1.0 x 10 ⁵ TCID ₅₀ /mL
Human coronavirus NL63	1.0 x 10 ⁵ TCID ₅₀ /mL
Adenovirus C1	1.0 x 10 ⁵ TCID ₅₀ /mL
Human Metapneumovirus(hMPV)	1.0 x 10 ⁵ TCID ₅₀ /mL
Parainfluenza virus 1, C35	1.0 x 10 ⁵ TCID ₅₀ /mL
Parainfluenza virus 2, Greer	1.0 x 10 ⁵ TCID ₅₀ /mL
Parainfluenza virus 3, C243	1.0 x 10 ⁵ TCID ₅₀ /mL
Parainfluenza virus 4, CH19503	1.0 x 10 ⁵ TCID ₅₀ /mL
Influenza A A/California/2/2014(H3N2)	1.0 x 10 ⁵ TCID ₅₀ /mL
Influenza A A/Hong Kong/8/68(H3N2)	1.0 x 10 ⁵ TCID ₅₀ /mL
Influenza A A/California/07/2009(H1N1)	1.0 x 10 ⁵ CEID ₅₀ /mL
Human enterovirus 71Strain: H	1.0 x 10 ⁵ TCID ₅₀ /mL
Human respiratory syncytial virus, A2	1.0 x 10 ⁵ PFU/mL
Rhinovirus 2060	1.0 x 10 ⁵ PFU/mL
Haemophilus influenza	1.0 x 10 ⁶ cfu/mL
Streptococcus pneumoniae	1.0 x 10 ⁶ cfu/mL
Streptococcus pyogenes, Bruno	4.0 x 10 ⁶ cfu/mL
Candida albicans	1.0 x 10 ⁶ cfu/mL
Bordetella pertussis, 18323	1.0 x 10 ⁶ cfu/mL
Mycoplasma pneumoniae	1.0 x 10 ⁶ cfu/mL
Chlamydia pneumoniae TW-183	1.0 x 10 ⁶ IFU/mL
Legionella pneumophila	1.0 x 10 ⁶ cfu/mL
Pneumocystis jirovecii	1.0 x 10 ⁶ cfu/mL
Staphylococcus epidermidis	1.0 x 10 ⁶ cfu/mL
Staphylococcus aureus	1.0 x 10 ⁶ cfu/mL
Pooled human nasal wash	NA

To estimate the likelihood of cross-reactivity with SARS-CoV-2, influenza A or B virus in the presence of organisms that were not available for wet testing, due to unavailability of BSL-3 access, in silico analysis using the Basic Local Alignment Search Tool (BLAST) managed by the National Center for Biotechnology Information (NCBI) was used to assess the degree of protein sequence homology. Wet testing of SARS-coronavirus, MERS-CoV was not evaluated and therefore the performance of the ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test in the presence of MERS is unknown.

- The comparison between SARS-CoV-2 nucleocapsid protein, MERS-CoV and human coronavirus HKU1 revealed that cross-reactivity
 cannot be ruled out. Homology for HKU1 and MERS-CoV is relatively low, at 48.5% across 91% of sequence and 36.7% across 82%
 of the sequence, respectively.
- Wet testing with SARS-coronavirus was not conducted. However, in silico analysis indicated that cross-reactivity is likely.
- No significant similarity found between Mycobacterium tuberculosis, and SARS-CoV-2, or between Mycobacterium tuberculosis and influenza A or B, however, cross-reactivity cannot be ruled out.
- No significant similarity found between SARS-Coronavirus and influenza A or B, however, cross-reactivity cannot be ruled out.
- No significant similarity found between MERS-coronavirus and influenza A or B, however, cross-reactivity cannot be ruled out.
- No significant similarity found between Human coronavirus HKU and influenza A or B, however, cross-reactivity cannot be ruled out.

ENDOGENOUS INTERFERING SUBSTANCES

The potential interference of endogenous substances with the antibodies used for the detection of COVID-19, influenza A and B was examined by testing nineteen (19) substances in a negative clinical matrix, in the absence or presence of each virus; at 3 x LOD concentrations for SARS-CoV-2, influenza A and influenza B. The interference study was conducted using medically relevant concentrations of the potentially interfering substances listed below to assess the potential interference of the substances on the performance of ViraDx SARS-CoV-2/Flu A+B Rapid Antigen Test. No interference was seen with the listed substances when tested at the concentration presented in the table below.

Interfering Substance	Active Ingredient	Concentration
Mucin	Mucin	5.0 mg/mL
Whole blood (human)	Blood	5%
Halls Cough Suppressant/ Oral Anesthetic Drops	Menthol	1.5 mg/mL
Nasacort Allergy 24H	Triamcinolone acetonide	5%
Rhinocort Allergy Spray	Budesonide (Glucocorticoid)	5%
ZICAM Cold Remedy + Multi-Symptom Relief	Galphimia glauca, luffa operculata, sabadilla	5%
Afrin Nasal Spray	Oxymetazoline HCL	15%
Cepacol Extra Strength	Benzocaine, Menthol	1.5 mg/mL
Flonase Allergy Relief	Fluticasone Propionate (Glucocorticoid)	5%
Oseltamivir	Oseltamivir	5 mg/mL
Saline nasal spray	Saline	15%
NasoGEL(NeilMed)	Sodium Chloride, Sodium Bicarbonate, Sodium Hyaluronate	5%
Tobramycine	Tobramycin	10 µg/mL
Zanamivir	Zanamivir	282.0 ng/mL
CVS Sinus Relief Nasal spray	Phenylephrine hydrochloride	15%
NasalCrom Nasal spray	Cromolyn sodium	15%
Sore throat phenol spray	Phenol	15%
Homeopathic (Alkalol)	Galphima glauca 6X, Luffa operculata 6X, Sabadila 6X	1:10 dilution
Mupirocin	Mupirocin	10 mg/mL

HIGH-DOSE HOOK EFFECT

A high-dose hook effect was not detected in Status COVID-19/Flu A&B for the SARS-CoV-2, influenza A and B viral strains at the concentration listed below.

Virus Type	Viral Strain	Concentration tested
SARS-CoV-2	USA-WA1/2020	1.15 x 10 ⁷ TCID ₅₀ /mL
Influenza A (H3N2)	A/California/2/2014	5.8 x 10 ⁵ TCID ₅₀ /mL
Influenza A (H3N2)	A/Hong Kong/8/68	1.26 x 106 TCID ₅₀ /mL
Influenza A (H3N2)	Victoria/361/11	1.41 x 10 ⁵ TCID ₅₀ /mL
Influenza A (H1N1)	A/California/07/2009	5.2 x 107 CEID ₅₀ /mL
Influenza B	B/Russia/69	1.5 x 10 ⁶ CEID ₅₀ /mL
Influenza B	B/Florida/02/06	1.05 x 106 TCID50/mL
Influenza B	B/Victoria/504/00	1.41 x 10 ⁵ TCID ₅₀ /mL
Influenza B	B/Yamagata/16/88	1.70 x 10 ⁵ TCID ₅₀ /mL

CO-INFECTION (COMPETITIVE INTERFERENCE)

For co-infection, SARS-CoV-2 at levels near LOD was tested in the presence of high levels of influenza A or influenza B and influenza A and influenza B at levels near LOD were tested in the presence of high levels of SARS-CoV-2. No competitive interference was seen between SARS-CoV-2 and influenza A and B in this testing at the concentration listed in the tables below.

Cross-Reactivity Influenza A

Competing virus	Concentration	Target virus	Concentration	Target Analyte Percent Positivity
Influenza A (H3N2) A/California/2/2014	1.0 x 10 ⁵ TCID ₅₀ /mL	SARS-CoV-2 USA-WA1/2020	4.0 x 10 ³ TCID ₅₀ /mL	100%
Influenza A A/Hong Kong/8/68(H3N2)	1.0 x 10 ⁵ TCID ₅₀ /mL	SARS-CoV-2 USA-WA1/2020	4.0 x 10 ³ TCID ₅₀ /mL	100%
Influenza A (H3N2) Victoria/361/11	1.0 x 10 ⁵ TCID ₅₀ /mL	SARS-CoV-2 USA-WA1/2020	4.0 x 10 ³ TCID ₅₀ /mL	100%
Influenza A (H1N1) A/California/07/2009	1.0 x 10 ⁵ CEID₅₀/mL	SARS-CoV-2 USA-WA1/2020	4.0 x 10 ³ TCID ₅₀ /mL	100%
SARS-CoV-2 USA-WA1/2020	1.0 x 10 ⁵ TCID ₅₀ /mL	Influenza A (H3N2) Victoria/361/11	6.5 x 10 ¹ TCID ₅₀ /mL	100%
SARS-CoV-2 USA-WA1/2020	1.0 x 10 ⁵ TCID₅₀/mL	Influenza A (H1N1) A/California/07/2009	3.0 x 10 ⁵ CEID ₅₀ /mL	100%

Cross-Reactivity Influenza B

Competing virus	Concentration	Target virus	Concentration	Target Analyte Percent Positivity
Influenza B B/Russia/69	1.0 x 10 ⁵ CEID ₅₀ /mL	SARS-CoV-2 USA-WA1/2020	4.0 x 103 TCID ₅₀ /mL	100%
Influenza B B/Florida/02/06	1.0 x 10 ⁵ TCID₅₀/mL	SARS-CoV-2 USA-WA1/2020	4.0 x 103 TCID ₅₀ /mL	100%
Influenza B Victoria/504/00	1.0 x 10 ⁵ TCID₅₀/mL	SARS-CoV-2 USA-WA1/2020	4.0 x 10 ³ TCID ₅₀ /mL	100%
Influenza B Yamagata/16/88	1.0 x 10⁵ TCID₅₀/mL	SARS-CoV-2 USA-WA1/2020	4.0 x 103 TCID ₅₀ /mL	100%
SARS-CoV-2 USA-WA1/2020	1.0 x 10⁵ TCID₅₀/mL	Influenza B Victoria/504/00	8.0 x 10 ² TCID ₅₀ /mL	100%
SARS-CoV-2 USA-WA1/2020	1.0 x 10 ⁵ TCID₅₀/mL	Influenza B Yamagata/16/88	4.0 x 10 ² TCID ₅₀ /mL	100%

ASSISTANCE

If you have any questions regarding the use of this product, please contact Lumos Diagnostics Technical Support at 1.855.LumosDx or email technical.support@lumosdiagnostics.com.

REFERENCES

- 1. Shaw MW, Arden NH, Massab HF. New aspects of influenza viruses. Clin Microbiol Rev 1992;5(1):74-92.
- 2. WHO recommendations on the use of rapid testing for influenza diagnosis, July 2005.
- 3. Design Considerations for Pivotal Clinical Investigations for Medical Devices: Guidance for Industry, Clinical Investigators, Institutional Review Boards and Food and Drug Administration Staff, November 7, 2013 (Page 45).

GLOSSARY OF SYMBOLS

i	Consult instructions for use	Do not use if package is damaged	REF Catalog number
2°C - 1 30°C	Temperature limit	Do not re-use	CONTROL + Positive Control
23	Use-by date	IVD in vitro diagnostic medical device	CONTROL - Negative Control
\sum_{1}	Contains sufficient for 1 test	LOT Batch code	Distributor
\sum_{25}	Contains sufficient for 25 tests	R _X Only For prescription use only	



Lumos Diagnostics, inc.

Lumos Diagnostics, inc. 2724 Loker Avenue West, Carlsbad, CA 92010 USA Avenue West, Carlsbad, CA 92010 USA

For a complete list of U.S. international and other patents, please visit LumosDiagnostics.com.

© 2024 Lumos Diagnostics, Inc. All rights reserved.

PM-169.3 OCT 2024